Elizabeth McKenna

Zongertinib breakthrough: Elizabeth McKenna highlights new study on HER2-driven cancers

Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X about a recent article by Birgit Wilding et al. published in Cancer Discovery, adding:

“ICYMI in Cancer Discovery – AACR ahead of today’s big clinical plenary at AACR25 – the preclinical characterization and early clinical proof-of-concept of zongertinib, an irreversible HER2 TKI that spares EGFR signaling and has activity in HER2-driven cancers.”

Elizabeth McKenna

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Authors: Birgit Wilding et al.

Elizabeth McKenna

Learn more about Zongertinib in cancer treatment on OncoDaily.

AACR25 Anke Baum Anna C. Obenauf Annemarie Bruining Birgit Wilding cancer Cancer Discovery Daniel Gerlach Dirk Scharn Fiona Spreitzer Flavio Solca Frans L. Opdam Gintautas Vainorius Irene C. Waizenegger Johannes Popow John V. Heymach Krzysztof Chylinski Lydia Woelflingseder Mark A. Pearson Martin Augsten Masachika Ikegami Neil Gibson Noboru Yamamoto Norbert Kraut OncoDaily Oncology Ralph A. Neumüller Shinji Kohsaka Shunsuke Kondo Sylvia Tilandyová Yukina Shirai Zongertinib